They identified two groups: one with mutations in FLT3, PTPN11, WT1, IDH1, NPM1, IDH2, and NRAS, which conferred a lower risk of progressive disease, and the other with mutations in TP53, GATA2, KRAS, RUNX1, STAG2, ASXL1, ZRSR2, and TET2, which were predictive of a higher risk of aggressive AML evolution [99]. Here, TP53 is linked to acute myeloid leukemia.